

APPENDIX A

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: the topology of the sequence was not reported.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

APPENDIX B

SEQUENCE LISTING

<110> Bestor, Timothy H.

<120> CHIMERIC DNA-BINDING/DNA METHYLTRANSFERASE NUCLEIC ACID
AND POLYPEPTIDE AND USES THEREOF

<130> 48075/B/PCT/US

<140> 09/051,013

<141> 1998-10-09

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 632

<212> DNA

<213> HIV

<400> 1

```

tggaagggt aattcactcc caacgaagac aagatatacct tgatctgtgg atctaccaca 60
cacaaggcta cttccctgat tagcagaact acacaccagg gccaggagtc agatatccac 120
tgacctttgg atggtgctac aagctagtagc cagttgagcc agataaggta gaagaggcca 180
acaaaggaga gaacaccagc ttgttacacc ctgtgagcct gcatgggatg gatgaccagg 240
atatataagt gttagagtgg aggtttgaca gccgcctagc atttcatcac gtggcccgag 300
agctgcatcc ggagtacttc aagaactgct gatatcgagc ttgctacaag ggactttccg 360
ctggggactt tccagggagg cgtggcctgg gcgggactgg ggagtggcga gccctcagac 420
ctgcatataa gcagctgctt tttgcctgta ctgggtctct ctgggttagac cagatctgag 480
cctgggagct ctctggctag ctagggaacc cactgcttaa gcctcaataa agcttgcctt 540
gagtgcctca agtagtgtgt gcccgctctgt tgtgtgactc tggtaactag agatccctca 600
gaccctttta gtcagtgtgg aaaatctcta gc                                     632

```

<210> 2

<211> 513

<212> PRT

<213> Spiroplasma

<220>

<223> X in this sequence is unknown

<400> 2

```

Met Arg Gly Ser His His His His His His Gly Ile Cys Thr Thr Met
  1           5           10          15

```

Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20

25

30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 65 70 75 80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 85 90 95

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 100 105 110

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 115 120 125

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 130 135 140

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 145 150 155 160

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 165 170 175

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 180 185 190

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 195 200 205

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 210 215 220

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 225 230 235 240

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 245 250 255

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 260 265 270

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

275

280

285

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 290 295 300

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 305 310 315 320

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 325 330 335

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 340 345 350

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 355 360 365

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 370 375 380

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 385 390 395 400

Xaa Xaa Xaa Gly Gly Arg Ser Thr Ser His Glu Arg Xaa Xaa Xaa Xaa
 405 410 415

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 420 425 430

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 435 440 445

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 450 455 460

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 465 470 475 480

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 485 490 495

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Lys Asp Lys Lys Ala Gly
 500 505 510

Ser

<210> 3
<211> 20
<212> PRT
<213> Spiroplasma

<400> 3
Met Arg Gly Ser His His His His His His Gly Ile Cys Thr Gly Thr
1 5 10 15

Ser His Glu Arg
20

<210> 4
<211> 23
<212> PRT
<213> Spiroplasma

<400> 4
Gln Lys Asp Lys Lys Ala Gly Ser Ser Val Asp Phe Ala Ile Gly Phe
1 5 10 15

Gly Phe Cys Phe Thr Met Ser
20

<210> 5
<211> 9
<212> PRT
<213> Spiroplasma

<400> 5
Gly Gly Leu Gln Pro Ser Leu Ile Ser
1 5

<210> 6
<211> 17
<212> PRT
<213> Spiroplasma

<400> 6
Met Arg Gly Ser His His His His His His Gly Ile Cys Thr Thr Met
1 5 10 15

Ser

<210> 7

<211> 8

<212> PRT

<213> Spiroplasma

<400> 7

Asp Lys Asp Lys Lys Ala Gly Ser

1

5

<210> 8

<211> 128

<212> DNA

<213> Spiroplasma

<400> 8

ccatggaatt gtgagcgctc acaattcgcg tcgcgccgac gccgtcgcg cgacgcgacg 60

cgttggtacc ttaacactcg cgagtgttaa gcgcagcgcg gctgcggcag cgccgctgcg 120

ctgcgcaa 128

APPENDIX C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Timothy H. Bestor

Serial No.: 09/051,013

Examiner: J. Kerr

Filed : October 9, 1998

Group Art: 1633

For : CHIMERIC DNA-BINDING/DNA METHYLTRANSFERASE NUCLEIC ACID
AND POLYPEPTIDE AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
April 4, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same content as that submitted herewith as **Exhibit B** entitled "Sequence Listing."

Respectfully submitted,



Jane M. Love
Registration No. 42,812
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400